Trial Profile
Efficacy and Safety of Adalimumab in Behçet'S Disease Related Uveitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Behcet's syndrome; Uveitis
- Focus Adverse reactions; Therapeutic Use
- 05 Jul 2017 New trial record
- 17 Jun 2017 Primary endpoint has been met. (reduction of ocular inflammatory flares) as per results presented at the 18th Annual Congress of the European League Against Rheumatism
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism